Search research articles
Contact Us
Filters
Showing results (131-140 of 235) with videos related to
Page
of 24
Sort By:
Annals of Internal Medicine
|
May 1, 1997
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer
S Vadhan-Raj, L J Murray, C Bueso-Ramos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.
The Lancet. Oncology
|
December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Cell
|
December 2, 2017
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J Topper, Michelle Vaz, Katherine B Chiappinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A J Schoenfeld, S J Antonia, M M Awad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 18, 2020
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
A J Schoenfeld, H Rizvi, C Bandlamudi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C Arbour, Laura Mezquita, Niamh Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2020
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy
Matthew D Hellmann, Pasi A Jänne, Mateusz Opyrchal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2019
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Juan C Osorio, Kathryn C Arbour, Dung T Le, et al.
Nature Communications
|
August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
Kevin Litchfield, James L Reading, Emilia L Lim, et al.
Page
of 24
Search research articles
Search
Showing results (131-140 of 235) with videos related to
Sort By:
Page
of 24
Annals of Internal Medicine
|
May 1, 1997
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer
S Vadhan-Raj, L J Murray, C Bueso-Ramos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.
The Lancet. Oncology
|
December 10, 2016
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.
Cell
|
December 2, 2017
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J Topper, Michelle Vaz, Katherine B Chiappinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2021
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
A J Schoenfeld, S J Antonia, M M Awad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 18, 2020
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
A J Schoenfeld, H Rizvi, C Bandlamudi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C Arbour, Laura Mezquita, Niamh Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2020
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy
Matthew D Hellmann, Pasi A Jänne, Mateusz Opyrchal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2019
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
Juan C Osorio, Kathryn C Arbour, Dung T Le, et al.
Nature Communications
|
August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity
Kevin Litchfield, James L Reading, Emilia L Lim, et al.
Page
of 24